You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Claims for Patent: 9,457,154

✉ Email this page to a colleague

Summary for Patent: 9,457,154

Title:	Injection device with an end of dose feedback mechanism
Abstract:	An injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement. Feedback signal may be generated by a change in a rotational velocity of at least one part, e.g. by changing the pitch of a threaded portion or by engaging a non-rotating part and a rotating part, thereby causing the non-rotating part to start rotating. May alternatively be generated by building up and releasing a tension. The injection device is suitable for injecting insulin.
Inventor(s):	Moller Claus Schmidt, Radmer Bo, Nielsen Lars Ulrik, Engaard Christian Peter
Assignee:	Novo Nordisk A/S
Application Number:	US11813389
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,457,154
Patent Claims:

Details for Patent 9,457,154

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	June 16, 2005	⤷ Get Started Free	2026-01-20
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	October 31, 2013	⤷ Get Started Free	2026-01-20
Novo Nordisk Inc.	NOVOLOG MIX 50/50	insulin aspart protamine and insulin aspart	Injectable Suspension	021810	August 26, 2008	⤷ Get Started Free	2026-01-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,457,154

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006079481	⤷ Get Started Free
United States of America	9861757	⤷ Get Started Free
United States of America	2019282762	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.